Prostate Cancer Blog

A New Phase III Trial of ODM-201 for Men with Castrate Resistant Prostate Cancer without Visible Metastases

Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company) have announced that they have begun enrollment in a randomized Phase III clinical trial of a new investigational treatment for men with advanced prostate cancer. ODM-201 is a novel, oral androgen receptor inhibitor. The trial named ARAMIS trial is a randomized, Phase III, multi-center, double-blind, placebo-controlled [...]

By |2021-02-17T11:03:15-05:00September 21st, 2014|Advanced Prostate Cancer, Androgan Receptor Inhibitor, Drugs & Treatments, General Information, Hormone Therapy, OMD-201, Uncategorized|1 Comment
Read More

Depression In Men Receiving Androgen Deprivation Therapy (ADT)

Yesterday I wrote about the cognitive effects of hormone therapy (ADT), today’s topic is about depression in men on ADT. It is commonly known that men on ADT often experience many physical and psychological side effects of the treatment. One of these side effects to ADT may be associated with increased risk for depression, but [...]

By |2020-02-04T11:40:42-05:00September 16th, 2014|ADT, Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, How We Live, Quality of Life, Research, Uncategorized, Understanding APC|2 Comments
Read More

Chemo-Brain and ADT for Advanced Prostate Cancer – Does It Exist?

When I went on my first round of hormone therapy (ADT) I experienced severe cognitive side effects. I found it impossible to concentrate, read and remember anything. I lost the ability to navigate the New York City subways no less drive my car to a destination. Occasionally, when I was attempting to navigate the subway [...]

By |2017-10-19T10:48:02-04:00September 15th, 2014|ADT, Advanced Prostate Cancer, General Information, Hormone Therapy, Me, Quality of Life, Research, Uncategorized, Understanding APC|5 Comments
Read More

Xtandi (enzaludamide) Receives FDA Approval in the Pre-Chemo Stage of Prostate Cancer Treatment

Expected and extraordinary news today on the new treatment front. Medivation and Astellas’ Xtandi (enzalutamide) was approved for use in men with castrate resistant prostate cancer. The new FDA approved label for Xtandi says that it is for the treatment of men with metastatic castration-resistant prostate cancer. This label is basically the same as for [...]

By |2014-09-10T17:03:53-04:00September 10th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, enzalutamide, General Information, survival, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments
Read More

Pain and Its Under-Treatment in Advanced Cancers

I really thought we had gotten over this problem, but an article appearing in a recent report in the Journal of Clinical Oncology indicates that the age old problem that often our doctors fail to supply adequate pain medications to advanced cancer survivors because a fear of drug addiction This attitude still hampers good survivorship [...]

By |2017-10-19T10:48:03-04:00September 8th, 2014|Advanced Prostate Cancer, ASCO, Bone Metastases, Drugs & Treatments, Pain, survivorship, Uncategorized, Understanding APC|0 Comments
Read More

Cabozantinib Fails In the Phase III COMET-1 Trial

The pharmaceutical company Exelixis has announced that their experimental treatment, cabozantinib has failed the Phase III clinical trial for men with metastatic castration-resistant prostate cancer (mCRPC). In the trial the experimental treatment cabozantinib was compared to the drug prednisone. In the trial known as COMET-1, Cabozantinib, a tyrosine kinase inhibitor, did not meet its primary [...]

By |2017-10-19T10:48:04-04:00September 2nd, 2014|Advanced Prostate Cancer, cabozantinib, Clinical Trials, Clinical Trials, Uncategorized|0 Comments
Read More

Thank You My Readers for Your Support in Being Awarded the Harry Pinchot Service Award

I recently was informed that I am to honored with the 2014 Harry Pinchot Award from the Prostate Cancer Research Institute.  The award recognizes outstanding dedication and support to the prostate cancer community. I am pleased and flattered to be one of this year's receptients.I have been told that one reason I have received this [...]

By |2017-10-19T10:48:04-04:00August 26th, 2014|Advanced Prostate Cancer, General Information, Uncategorized|9 Comments
Read More

Understanding the Real Concerns Men with Advanced Prostate Cancer Have About the Quality of Their Life

Advanced prostate cancer and its treatments has significant impacts on a man’s quality of life (QOL) as well as their perception of their health. It is important to better understand these concerns, especially those currently not captured by the currently available health-related quality of life (HRQL) instruments. In the quest to better understand these concerns [...]

By |2020-02-04T10:15:32-05:00August 21st, 2014|Advanced Prostate Cancer, Research, survivorship, Uncategorized, Understanding APC|0 Comments
Read More

Clinical Benefit of Docetaxel or Enzalutamide After Progression on First-Line Abiraterone and Prednisone in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) *

Abiraterone acetate (AA) or Zytiga has demonstrated a survival benefit in the pre-chemotherapy setting for men with advanced prostate cancer that has become castrate resistant (mCRPC). As a result it is in widespread clinical use in the United States prior to the use of chemotherapy with docetaxel.  Since its FDA approval post chemotherapy there has [...]

By |2017-10-19T10:48:05-04:00August 20th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Cross Resistance, Drugs & Treatments, enzalutamide, Uncategorized, Understanding APC, Xtandi|0 Comments
Read More
Go to Top